3-(1-((1-methyl-1H-benzo[d]imidazol-2-yl)methyl)piperidin-4-yl)-benzonitrile | 1004618-19-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-(1-((1-methyl-1H-benzo[d]imidazol-2-yl)methyl)piperidin-4-yl)-benzonitrile
• 英文别名: 3-[1-[(1-methylbenzimidazol-2-yl)methyl]piperidin-4-yl]benzonitrile
• CAS: 1004618-19-2
• 化学式: C₂₁H₂₂N₄
• 分子量: 330.432
• InChiKey: JEBDEWUTVKJJRZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-哌啶-4-基苯腈 、 1-甲基-2-甲酰苯并咪唑 在 三乙酰氧基硼氢化钠 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.0h， 生成 3-(1-((1-methyl-1H-benzo[d]imidazol-2-yl)methyl)piperidin-4-yl)-benzonitrile
  参考文献：
  名称：

  1-[(1-Methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines as mGluR2 Positive Allosteric Modulators for the Treatment of Psychosis

  摘要：

  A novel series of mGluR2 positive allosteric modulators (PAMs), 1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines, is herein disclosed. Structure-activity relationship studies led to potent, selective mGluR2 PAMs with excellent pharmacokinetic profiles. A representative lead compound (+)-17e demonstrated dose-dependent inhibition of methamphetamine-induced hyperactivity and mescaline-induced scratching in mice, providing support for potential efficacy in treating psychosis.

  DOI：

  10.1021/jm101414h

文献信息

• 1-[(1-Methyl-1<i>H</i>-imidazol-2-yl)methyl]-4-phenylpiperidines as mGluR2 Positive Allosteric Modulators for the Treatment of Psychosis
  作者：Lei Zhang、Michael A. Brodney、John Candler、Angela C. Doran、Allen J. Duplantier、Ivan V. Efremov、Edel Evrard、Kenneth Kraus、Alan H. Ganong、Jessica A. Haas、Ashley N. Hanks、Keith Jenza、John T. Lazzaro、Noha Maklad、Sheryl A. McCarthy、Weimin Qian、Bruce N. Rogers、Melinda D. Rottas、Christopher J. Schmidt、Judith A. Siuciak、F. David Tingley、Andy Q. Zhang

  DOI：10.1021/jm101414h

  日期：2011.3.24

  A novel series of mGluR2 positive allosteric modulators (PAMs), 1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines, is herein disclosed. Structure-activity relationship studies led to potent, selective mGluR2 PAMs with excellent pharmacokinetic profiles. A representative lead compound (+)-17e demonstrated dose-dependent inhibition of methamphetamine-induced hyperactivity and mescaline-induced scratching in mice, providing support for potential efficacy in treating psychosis.